Clinical and cytogenetic characteristics of newly diagnosed AML patients
| Characteristic . | Microarray cohort (n = 122) . | Quantitative RT-PCR (outcome validation) cohort (n = 60) . |
|---|---|---|
| Age, y | ||
| Median | 60.3 | 59 |
| Range | 18-86 | 24-80 |
| Sex, no. (%) | ||
| Female | 47 (38) | 29 (48) |
| Male | 75 (62) | 31 (52) |
| White cell count, ×103/L | ||
| Median | 45.27 | 53.7 |
| Range | 0.7-278 | 1.3-273 |
| Bone marrow blasts, % | ||
| Median | 62 | 70.2 |
| Range | 20-99 | 25-93 |
| WHO classification, no. (%) | ||
| AML with recurrent genetic abnormalities | ||
| t(15;17)(q22;q12) | 4 (3.3) | 0 |
| inv(16)(p13q22)/ t(16;16)(p13;q22) | 4 (3.3) | 0 |
| t(6;11) or t(9;11) | 9 (7.5) | 3 (5) |
| AML with multilineage dysplasia | 29 (24) | 7 (12) |
| AML and MDS, therapy-related | 12 (10) | 8 (13) |
| AML not otherwise categorized | ||
| AML minimally differentiated | 5(4) | 5 (8.3) |
| AML without maturation | 9 (7.5) | 9 (15) |
| AML with maturation | 10 (8) | 12 (20) |
| AML myelomonocytic leukemia | 21 (17) | 4 (6.6) |
| Acute monoblastic and monocytic leukemia | 8 (6.5) | 9 (15) |
| Acute erythroid leukemia | 6 (5) | 0 |
| Acute megakaryoblastic leukemia | 3 (2.5) | 0 |
| Not categorized* | 2 (1.5) | 3 (5) |
| Cytogenetics,† no. (%) | ||
| Normal karyotype | 45 (37) | 29 (48) |
| +8 | 5 (4) | 1 (1.6) |
| Complex karyotype | 23 (20) | 12 (20) |
| Other karyotypes | 26 (19) | 14 (24) |
| Not done | 6 (5) | 1 (1.6) |
| FLT3 status,‡ no. (%) | ||
| FLT3-ITD+ | 17 (18) | 14 (27) |
| FLT3-wt | 73 (82) | 38 (73) |
| FLT3-D835 | 2 (2) | 2 (4) |
| Not done | 32 | 8 |
| Status at last follow-up, no. (%)§ | ||
| Dead | 81 (66) | 42 (70) |
| Alive | 41 (33) | 18 (30) |
| Characteristic . | Microarray cohort (n = 122) . | Quantitative RT-PCR (outcome validation) cohort (n = 60) . |
|---|---|---|
| Age, y | ||
| Median | 60.3 | 59 |
| Range | 18-86 | 24-80 |
| Sex, no. (%) | ||
| Female | 47 (38) | 29 (48) |
| Male | 75 (62) | 31 (52) |
| White cell count, ×103/L | ||
| Median | 45.27 | 53.7 |
| Range | 0.7-278 | 1.3-273 |
| Bone marrow blasts, % | ||
| Median | 62 | 70.2 |
| Range | 20-99 | 25-93 |
| WHO classification, no. (%) | ||
| AML with recurrent genetic abnormalities | ||
| t(15;17)(q22;q12) | 4 (3.3) | 0 |
| inv(16)(p13q22)/ t(16;16)(p13;q22) | 4 (3.3) | 0 |
| t(6;11) or t(9;11) | 9 (7.5) | 3 (5) |
| AML with multilineage dysplasia | 29 (24) | 7 (12) |
| AML and MDS, therapy-related | 12 (10) | 8 (13) |
| AML not otherwise categorized | ||
| AML minimally differentiated | 5(4) | 5 (8.3) |
| AML without maturation | 9 (7.5) | 9 (15) |
| AML with maturation | 10 (8) | 12 (20) |
| AML myelomonocytic leukemia | 21 (17) | 4 (6.6) |
| Acute monoblastic and monocytic leukemia | 8 (6.5) | 9 (15) |
| Acute erythroid leukemia | 6 (5) | 0 |
| Acute megakaryoblastic leukemia | 3 (2.5) | 0 |
| Not categorized* | 2 (1.5) | 3 (5) |
| Cytogenetics,† no. (%) | ||
| Normal karyotype | 45 (37) | 29 (48) |
| +8 | 5 (4) | 1 (1.6) |
| Complex karyotype | 23 (20) | 12 (20) |
| Other karyotypes | 26 (19) | 14 (24) |
| Not done | 6 (5) | 1 (1.6) |
| FLT3 status,‡ no. (%) | ||
| FLT3-ITD+ | 17 (18) | 14 (27) |
| FLT3-wt | 73 (82) | 38 (73) |
| FLT3-D835 | 2 (2) | 2 (4) |
| Not done | 32 | 8 |
| Status at last follow-up, no. (%)§ | ||
| Dead | 81 (66) | 42 (70) |
| Alive | 41 (33) | 18 (30) |
No statistically significant differences were observed between the two set of patients (microarrays vs quantitative RT-PCR) by t test and χ2, except for the category of AML without maturation (χ2, P = .03). All the values represent frequencies (%).
Those AML cases do not fulfill criteria for inclusion in one of the previously described subgroups.
Other cytogenetics groups not otherwise categorized in the WHO classification. A total of 116 of 122 patients from the microarray cohort and 59 of 60 patients from the quantitative RT-PCR cohort had at least 20 or more metaphases analyzed by conventional karyotype. Complex karyotype is defined as more than or equal to 3 chromosomal abnormalities.
Not all the patients had FLT3 analyzed. The percentages shown are in relationship to the total number of patients with FLT3 mutation studies.
The median follow-up for alive patients in the 122 AML patients is 100 weeks (range, 1-586 weeks) and in the 60 AML cohorts is 124 weeks (range, 7-278 weeks).